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Abstract
Background Gene promoter methylation is an important
regulator of expression and is a key epigenetic factor in
tumorigenesis. DNA methylation is mediated by DNA
methyltransferases (DNMTs), of which three active forms have
been identified: DNMT1, DNM3A and DNMT3B. The C→T
transition polymorphism (C46359T) in the promoter of the
DNMT3B  gene, which significantly increases transcriptional
activity, has been postulated to increase the propensity for
promoter-hypermethylation-mediated silencing of tumour
suppressor genes.
Methods To determine the role of this polymorphism in breast
cancer, we genotyped 352 cases and 258 controls from a
British population. The breast cancer cases were selected on
the basis of either an age at onset of less than 40 years, a family
history of breast cancer irrespective of age at onset, or bilateral
breast cancer diagnosed after 39 years of age irrespective of
family history.
Results The C allele was found to be more common in case
subjects than in control subjects (cases, 0.59; controls, 0.54)
corresponding to a nominally significant increase in breast
cancer risk to heterozygotes and CC homozygotes (odds ratio
1.51, 95% confidence interval 1.01–2.25) in the dominant
inheritance model.
Conclusions Our findings contrast with those of a previous
study, which showed that individuals carrying at least one T
allele have a significantly increased risk of developing lung
cancer. This discrepancy might be an artefact resulting from a
chance variation, or it might point to differing influences of
promoter hypermethylation in these cancer types.
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Introduction
Genetic factors are increasingly being recognised as a
major contributor to cancer risk [1,2]. Although genes with
highly penetrant mutations, exemplified by BRCA1  and
BRCA2, confer a high relative risk, they are rare in the gen-
eral population and therefore the population attributable
risk is low. It is now suspected that most of the population
attributable genetic risk is due to relatively common 'low-
penetrance' disease-associated allelic variants. Although
these variants might confer a small absolute cancer risk,
this is outweighed by the fact that they are very common in
the general population [2]. Recognition of this fact has led
to an explosion of epidemiological studies searching for
common polymorphisms in genes that might represent sus-
ceptibility alleles [3,4]. Among the most promising candi-
dates are genes involved in the maintenance of genomic
integrity and DNA repair, which include genes such as
BRCA1, BRCA2 and TP53 [5-8]. These and other func-
tionally related genes are currently under intense scrutiny
for common low-penetrance cancer-predisposing alleles.
However, another group of genes, which have not received
much attention, are those responsible for epigenetic modi-
fication of DNA through CpG methylation.
DNA methylation is a major epigenetic modification involv-
ing the addition of a methyl group to the 5' position of a
cytosine in a CpG dinucleotide. These dinucleotides are
not equally distributed throughout the genome: most are
clustered in so-called 'CpG islands', which span the pro-
moter region and the first few exons of most housekeeping
and tumour suppressor genes [9]. Most CpG dinucleotides
present in islands are unmethylated in normal tissues,
whereas those present in other regions of the genome are
usually methylated. However, during the process of
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carcinogenesis this balance is reversed. Consequently,
even though many gene promoters become hypermethyl-
ated, overall cancers are hypomethylated compared with
matching normal tissues. Hypermethylation of CpG islands
located in the promoter regions of tumour suppressor
genes is now firmly established as an important, if not the
most important, mechanism of tumour suppressor gene
inactivation [10] and might also influence genomic stability.
DNA methylation is mediated by a family of DNA methyl-
transferases (DNMTs), of which three active forms
(DNMT1, DNMT3A and DNMT3B) have been identified in
mammalian cells [11]. An overall increase in the enzymatic
DNA methyltransferase activity of the two maintenance
DNA methyltransferases, DNMT1 and DNMT3B, has been
shown to occur in tumours [12-17].
The  DNMT3B  gene, located on chromosome 20q11.2,
contains a C→T transition polymorphism (C46359T) at a
novel promoter region, -149 base pairs from the transcrip-
tion start site, which in assays in vitro confers a 30%
increase in promoter activity [11,18]. The first evidence that
this polymorphism might be associated with cancer was
reported in lung cancer in which carriers of the T allele, par-
ticularly heterozygotes, had a significant increase in risk
(odds ratio [OR] 2.13, 95% confidence interval [CI] 1.47–
3.08) [11]. Although the mechanism for this association
was not clear, it was postulated that the T variant might
upregulate DNMT3B expression and thereby increase the
propensity for the epigenetic silencing of some tumour sup-
pressor genes. Such an association is supported by the
observation that DNMT3b is upregulated in lung cancer
cell lines [19], and comparative genomic hybridization stud-
ies have shown that the 20q region is often amplified in pri-
mary lung cancers [20].
In the present study we evaluated the association between
the DNMT3B C46359T polymorphism and breast cancer
risk in a hospital-based case-control study in a British
population.
Materials and methods
Subjects
Subjects were recruited in a hospital-based case-control
study of genes predisposing to breast cancer, performed at
breast clinics in the South of England. The breast cancer
cases were selected on the basis of either an age at onset
of less than 40 years (203 cases), a family history of breast
cancer (defined as two or more cases of breast cancer in a
first-degree or second-degree female relative) irrespective
of age at onset (105 cases), or bilateral breast cancer diag-
nosed after 39 years of age irrespective of family history
(44 cases). All breast cancer cases were systematically
ascertained through breast clinics in the South of England
as described previously [21,22]. In brief, women were
invited to take part in a research study, the primary goal of
which was to ascertain and verify family histories for segre-
gation analysis. The breast cancer cases diagnosed before
40 years of age were consecutively ascertained without
regard to family history. The group of women with bilateral
breast cancer were ascertained in the same clinics but the
selection criterion was the presence of bilateral breast can-
cer diagnosed after 39 years of age. The familial breast
cancer cases consisted of women presenting to the same
clinics with a strong family history of breast or ovarian can-
cer or both. Family histories were verified as far as possible
from medical records and death certificates. Blood was
taken from all recruits who consented to molecular analysis
for breast cancer predisposition genes. The age range of
case participants was 19–76 years, with a mean of 40.
The control subjects (n = 258) were all white female volun-
teers who were either staff at the Princess Anne Hospital,
Southampton (n = 117) or outpatients (n = 141) attending
for obstetric-related, non-neoplastic disease conditions.
The age of the controls ranged from 18–84 years, with a
mean of 39.
For all groups, normal genomic DNA was prepared from
blood lymphocytes. Epidemiological data such as repro-
ductive factors, oral contraceptive use, smoking and obes-
ity were not available for either the cases or controls.
However, both control and cancer groups were residents
of the greater Southampton area, which is a predominantly
Anglo-Saxon population.
Molecular analysis
A total of 352 case and 258 control subjects were geno-
typed for the DNMT3B C46359T polymorphism by using a
dual-colour allele-specific polymerase chain reaction
(PCR) assay. PCR amplifications were performed with a
common forward primer (5'-TGCTGTGACAGGCAGAG-
CAG-3') and HEX and FAM labelled reverse primers (5'-
GCCTTAGGTGACTGGAGGCCTG-3' and 5'-GGCT-
TAGGTGACTGGAGGCCTA-3', respectively). All PCRs
were performed in 10 µl volumes containing 10–200 ng of
genomic DNA, 200 nM dNTPs (Promega, Annandale,
NSW, Australia), 25 ng of each primer, 1× ReddyMix buffer
(Abgene, Epsom, Surrey, UK) and 0.2 units of Thermo-
prime Plus DNA Polymerase (Abgene). PCR amplification
cycle conditions involved an initial denaturation step at
94°C for 5 min, 40 cycles of denaturation at 94°C for 20 s,
annealing at 68°C for 20 s, and extension at 72°C for 45 s.
This was followed by a further extension step at 72°C for 5
min. The alleles were then separated through an unstained
3% agarose gel and analysed with a scanning laser fluores-
cence imager (Molecular Imager FX; Bio-Rad); 10% of the
genotyping was confirmed with a PCR and restriction frag-
ment length polymorphism assay described previously [3].Available online http://breast-cancer-research.com/content/6/4/R390
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Statistical methods
The Hardy–Weinberg equilibrium assumption was
assessed by the standard methods.
The data were considered by using models assuming either
dominant inheritance (that is, women with one or two C
alleles had the same relative hazard), co-dominant inherit-
ance (that is, the relative hazard differed between women
with one C allele and those with two C alleles) or recessive
inheritance (that is, only women with two C alleles were at
increased risk).
Case subjects were also stratified by family history, bilateral
breast cancer status and age of breast cancer onset. For all
analyses, the control subjects were treated as a single
group without stratification.
Comparisons of frequencies were analysed with Fisher's
exact test. ORs and 95% CIs were calculated by using the
relevant 2 × 2 contingency tables. All statistical calcula-
tions were two-sided and performed with InStat version
3.01 (GraphPad Software Inc., San Diego, CA). P < 0.05
was considered statistically significant. Power calculations
were performed with the online Binomial Distribution-Case
Control Power Calculator available from the UCLA Depart-
ment of Statistics http://calculators.stat.ucla.edu/.
Results
There was no evidence of a deviation from Hardy–Wein-
berg equilibrium among the case or control subjects. The
frequency of the C allele in control subjects (0.54) was sim-
ilar to that found in the previous study among Caucasians
(0.56); however, the frequency in case subjects was sub-
stantially lower (0.59 versus 0.51) [3]. All the breast cancer
cases have been screened for germline BRCA1  and
BRCA2  mutations [22]. A total of 18 BRCA1  and 9
BRCA2 mutations were detected and the frequencies of
the DNMT3b genotypes were 25.9% TT, 44.5% TC and
29.6% CC, which was not significantly different from the
breast cancer group as a whole (P = 0.22).
Table 1 shows the breast cancer risk (given by OR, 95% CI
and P value) for the different DNMT3B C46359T polymor-
phism genotypes according to co-dominant and dominant
models of inheritance. Under a dominant model of inherit-
ance, there was a nominally significant increase in breast
cancer risk (OR 1.51, 95% CI 1.01–2.25) when grouping
CC and CT genotypes and comparing them with the TT
genotype. A similar excess of C allele genotypes was also
observed in cases under co-dominant and recessive mod-
els, but these did not reach statistical significance. The fre-
quency of the C allele was higher among the breast
cancers than the controls (0.59 versus 0.54) but this differ-
ence was not statistically significant (P = 0.13).
The distribution of genotypes among subjects diagnosed
with breast cancer at the age of less than 40 years and
among subjects with a family history of breast cancer
(defined as an individual with two or more cases of breast
cancer in a first-degree or second-degree female relative)
and/or with bilateral breast cancer, was similar to that
observed for the entire cohort. Under each model of inher-
itance, a higher frequency of genotypes containing a C
allele was observed than in the controls, although these dif-
ferences were not statistically significant. Analysis of the
data according to the criteria on which the cases were
recruited revealed that the main contribution to the signifi-
cant result came from the under-40 and family history
groups (data not shown). The cases selected on the basis
of bilateral breast cancer showed a genotype distribution
very similar to the control group (TT, 25.0%; CT, 43.2%;
CC, 31.8%). The study had 80% power to detect an OR of
1.6 or more for carriers heterozygous for the C allele and an
OR of 1.7 or more for carriers homozygous for the C allele.
Table 1
DNMT3B genotype frequencies of breast cancer cases and controls
Group No. of 
subjects
TT No. 
(%)
TC No. 
(%)
Pa OR (95% CI) CC No. 
(%)
Pa OR
(95% CI)
TC+CC 
No. (%)
Pa (OR, 95% CI)
Control 258 60 (23.3) 116 (45.0) 82 (31.8) 198 (76.8)
All breast cancer 352 59 (16.8) 173 (49.1) 0.06 1.52
(0.99–2.33)
120 (34.1) 0.10 1.49
(0.94–2.35)
293 (83.2) 0.05 1.51
(1.01–2.25)
Under 40b 212 34 (16.0) 103 (48.6) 0.08 1.57
(0.95–2.58)
75 (35.4) 0.09 1.61
(0.96–2.73)
178 (84.0) 0.06 1.21
(1.01–1.45)
Family history 
bilateral 
cancerc
245 46 (18.5) 119 (47.8) 0.24 1.34
(0.84–2.12)
84 (33.7) 0.26 1.34
(0.82–2.18)
203 (81.5) 0.19 1.34
(0.87–2.06)
OR, odds ratio; CI, 95% confidence interval. aP was determined by Fisher's exact test (two-sided) for the relevant genotype, with the TT 
homozygotes as reference. bThis group includes cases that were originally selected on the basis of family history but where the diagnosis was 
made earlier than 40 years of age. cThis group includes cases that were originally selected on the basis of diagnosis earlier than 40 years of age 
but where there was also bilateral disease or a family history of cancer.Breast Cancer Research    Vol 6 No 4    Montgomery et al.
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Discussion
DNMT3B has been postulated to be important in cancer
because of its ability to mediate de novo DNA methylation,
which in turn might silence tumour suppressor gene
expression through promoter hypermethylation. Overex-
pression of DNMT3B has been observed in some cancer
types [13-17], providing circumstantial evidence for a role
in cancer development. In this context, the C46359T pro-
moter polymorphism, which is reported to increase pro-
moter activity, represents a highly plausible cancer-
predisposing allele [11].
Our study of British women diagnosed with early-onset
breast cancer, bilateral breast cancer and/or with a family
history of breast cancer has suggested that individuals car-
rying one or more C alleles for the DNMT3B C46359T pro-
moter polymorphism have a nominally significant increase
in breast cancer risk in comparison with TT homozygotes. If
we assume that the T allele is associated with increased
promoter activity, our findings are counter to the underlying
hypothesis that higher DNMT3B activity would increase de
novo methylation of tumour suppressor gene promoters,
and would thereby confer increased cancer risk. Because
the association with the C allele was of marginal signifi-
cance (P = 0.05), and because we could not adjust for
known breast cancer risk factors, we cannot exclude the
possibility that such confounding factors might have led to
a type I error. However, confounding due to differences in
ethnicity is unlikely because both the cases and the con-
trols were residents of Southampton or nearby towns,
which is a predominantly Anglo-Saxon population.
This is the first study of any DNMT3b polymorphism in
breast cancer. The only other cancer association study
reported an increased risk of lung cancer in carriers of the
allele with putatively higher activity (the T allele) [11].
Intriguingly, the lung cancer study found the most pro-
nounced effect with the CT heterozygotes under a co-dom-
inant model, which is similar to our observation. This raises
the possibility that intermediate DNMT3B activity might be
more biologically conducive to cancer development than
either extreme in activity. Alternatively, it is possible that
both associations are real and that the discrepancy is a
reflection of differing roles of DNMT3B in different cell
types. It has certainly been noted that different splice vari-
ants of DNMT3B, with potentially altered catalytic activity,
are expressed in a tissue-specific manner [17]. In addition,
it has been shown that repression of DNMT3B activity does
not result in the re-expression of all hypermethylated
tumour suppressor genes in some cell systems [23], sug-
gesting that there is a complex interplay of the different
DNMTs that might operate in a tissue-specific manner.
Finally, it is possible that linkage disequilibrium of the
C46359T promoter polymorphism alleles to other, as yet
unidentified, functional polymorphisms could explain the
lack of consensus with regard to disease association. This
possibility seems very likely given the very recent finding
that a T/C polymorphism (T46222C) located 138 base
pairs upstream of the C46359T polymorphism decreases
promoter activity by up to 90% [18]. In addition, an inverse
allele-dose response between DNMT3b mRNA expression
and the number of T alleles of the C46359T polymorphism
has been reported in bladder cancer, suggesting that it
might be the C allele that is associated with higher
DNMT3b expression [24]. Clearly, our understanding of the
genetic factors influencing the expression of DNMT3b is
incomplete, and definitive evidence defining how each
allelic variant influences expression is required. Neverthe-
less, the existing data suggest that genetic variants located
in the DNMT3b promoter can profoundly influence mRNA
expression.
Conclusions
Our study suggests that there may be an association
between the C allele of the DNMT3B promoter polymor-
phism and women with early-onset breast cancer, bilateral
breast cancer or with a family history of the disease. As this
is the first report of this polymorphism in breast cancer,
independent studies are needed to verify this association.
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